[1] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 68 (2018) 394-424.
[2] J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, A.X. Zhu, M. Sherman, M. Schwartz, M. Lotze, J. Talwalkar, and G.J. Gores, Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute 100 (2008) 698-711.
[3] P. Tabrizian, G. Jibara, B. Shrager, M. Schwartz, and S. Roayaie, Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Annals of surgery 261 (2015) 947-55.
[4] B.R. Nelson, C.A. Makarewich, D.M. Anderson, B.R. Winders, C.D. Troupes, F. Wu, A.L. Reese, J.R. McAnally, X. Chen, E.T. Kavalali, S.C. Cannon, S.R. Houser, R. Bassel-Duby, and E.N. Olson, A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science 351 (2016) 271-5.
[5] D.M. Anderson, K.M. Anderson, C.L. Chang, C.A. Makarewich, B.R. Nelson, J.R. McAnally, P. Kasaragod, J.M. Shelton, J. Liou, R. Bassel-Duby, and E.N. Olson, A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell 160 (2015) 595-606.
[6] A. Fatica, and I. Bozzoni, Long non-coding RNAs: new players in cell differentiation and development. Nature reviews. Genetics 15 (2014) 7-21.
[7] M.G. Fernandez-Barrena, M.J. Perugorria, and J.M. Banales, Novel lncRNA T-UCR as a potential downstream driver of the Wnt/beta-catenin pathway in hepatobiliary carcinogenesis. Gut 66 (2017) 1177-1178.
[8] W. Li, Z. Zhang, X. Liu, X. Cheng, Y. Zhang, X. Han, S. Liu, J. Yang, B. Xu, L. He, L. Sun, J. Liang, and Y. Shang, The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. The Journal of clinical investigation 127 (2017) 3421-3440.
[9] J.H. Xu, W.H. Chang, H.W. Fu, W.Q. Shu, T. Yuan, and P. Chen, Upregulated long non-coding RNA LOC90784 promotes cell proliferation and invasion and is associated with poor clinical features in HCC. Biochemical and biophysical research communications 490 (2017) 920-926.
[10] X. Zhao, Y. Liu, and S. Yu, Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker. Biochimica et biophysica acta. Molecular basis of disease 1863 (2017) 1805-1816.
[11] R. Tang, J.C. Wu, L.M. Zheng, Z.R. Li, K.L. Zhou, Z.S. Zhang, D.F. Xu, and C. Chen, Long noncoding RNA RUSC1-AS-N indicates poor prognosis and increases cell viability in hepatocellular carcinoma. European review for medical and pharmacological sciences 22 (2018) 388-396.
[12] Y. Wu, P.S. Wang, B.G. Wang, L. Xu, W.X. Fang, X.F. Che, X.J. Qu, Y.P. Liu, and Z. Li, Genomewide identification of a novel six-LncRNA signature to improve prognosis prediction in resectable hepatocellular carcinoma. Cancer medicine 7 (2018) 6219-6233.
[13] J. Yan, C. Zhou, K. Guo, Q. Li, and Z. Wang, A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma. Journal of cellular biochemistry 120 (2019) 213-223.
[14] J. Gao, P.W. Kwan, and D. Shi, Sparse kernel learning with LASSO and Bayesian inference algorithm. Neural networks : the official journal of the International Neural Network Society 23 (2010) 257-64.
[15] K. Kourou, T.P. Exarchos, K.P. Exarchos, M.V. Karamouzis, and D.I. Fotiadis, Machine learning applications in cancer prognosis and prediction. Computational and structural biotechnology journal 13 (2015) 8-17.
[16] J.X. Gu, X. Zhang, R.C. Miao, X.H. Xiang, Y.N. Fu, J.Y. Zhang, C. Liu, and K. Qu, Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma. World journal of gastroenterology 25 (2019) 220-232.
[17] A.J. Vickers, A.M. Cronin, E.B. Elkin, and M. Gonen, Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC medical informatics and decision making 8 (2008) 53.
[18] A.J. Vickers, B. Van Calster, and E.W. Steyerberg, Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ 352 (2016) i6.
[19] W. Huang da, B.T. Sherman, and R.A. Lempicki, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research 37 (2009) 1-13.
[20] N. Berndt, J. Eckstein, N. Heucke, R. Gajowski, M. Stockmann, D. Meierhofer, and H.G. Holzhutter, Characterization of Lipid and Lipid Droplet Metabolism in Human HCC. Cells 8 (2019).
[21] J. Gu, X. Zhang, R. Miao, X. Ma, X. Xiang, Y. Fu, C. Liu, W. Niu, and K. Qu, A three-long non-coding RNA-expression-based risk score system can better predict both overall and recurrence-free survival in patients with small hepatocellular carcinoma. Aging 10 (2018) 1627-1639.
[22] J.H. Choi, M.J. Kim, Y.K. Park, J.Y. Im, S.M. Kwon, H.C. Kim, H.G. Woo, and H.J. Wang, Mutations acquired by hepatocellular carcinoma recurrence give rise to an aggressive phenotype. Oncotarget 8 (2017) 22903-22916.
[23] A. Notarpaolo, R. Layese, P. Magistri, M. Gambato, M. Colledan, G. Magini, L. Miglioresi, A. Vitale, G. Vennarecci, C.D. Ambrosio, P. Burra, F. Di Benedetto, S. Fagiuoli, M. Colasanti, G. Maria Ettorre, A. Andreoli, U. Cillo, A. Laurent, S. Katsahian, E. Audureau, F. Roudot-Thoraval, and C. Duvoux, Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. Journal of hepatology 66 (2017) 552-559.
[24] R.H. Yuan, Y.M. Jeng, R.H. Hu, P.L. Lai, P.H. Lee, C.C. Cheng, and H.C. Hsu, Role of p53 and beta-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 15 (2011) 321-9.
[25] S.Y. Lee, I.T. Konstantinidis, A.A. Eaton, M. Gonen, T.P. Kingham, M.I. D'Angelica, P.J. Allen, Y. Fong, R.P. DeMatteo, and W.R. Jarnagin, Predicting recurrence patterns after resection of hepatocellular cancer. HPB : the official journal of the International Hepato Pancreato Biliary Association 16 (2014) 943-53.
[26] K.W. Ma, W.H. She, T.T. Cheung, A.C.Y. Chan, W.C. Dai, J.Y.Y. Fung, C.M. Lo, and K.S.H. Chok, Validated nomogram for the prediction of disease-free survival after hepatectomy for hepatocellular carcinoma within the Milan criteria: individualizing a surveillance strategy. Surgery today (2019).
[27] J.H. Shim, M.J. Jun, S. Han, Y.J. Lee, S.G. Lee, K.M. Kim, Y.S. Lim, and H.C. Lee, Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Annals of surgery 261 (2015) 939-46.
[28] S.X. Wu, J. Huang, Z.W. Liu, H.G. Chen, P. Guo, Q.Q. Cai, J.J. Zheng, H.D. Qin, Z.S. Zheng, X. Chen, R.Y. Zhang, S.L. Chen, and T.X. Lin, A Genomic-clinicopathologic Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer. EBioMedicine 31 (2018) 54-65.
[29] Y. Liu, J. Zhu, X. Ma, S. Han, D. Xiao, Y. Jia, and Y. Wang, ceRNA network construction and comparison of gastric cancer with or without Helicobacter pylori infection. Journal of cellular physiology 234 (2019) 7128-7140.
[30] C. Yue, Y. Ren, H. Ge, C. Liang, Y. Xu, G. Li, and J. Wu, Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma. OncoTargets and therapy 12 (2019) 561-576.
[31] H.P. Xian, Z.L. Zhuo, Y.J. Sun, B. Liang, and X.T. Zhao, Circulating long non-coding RNAs HULC and ZNFX1-AS1 are potential biomarkers in patients with gastric cancer. Oncology letters 16 (2018) 4689-4698.
[32] C. Xu, Y. Shao, T. Xia, Y. Yang, J. Dai, L. Luo, X. Zhang, W. Sun, H. Song, B. Xiao, and J. Guo, lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 35 (2014) 9701-6.
[33] L. Feng, Y. Zhu, Y. Zhang, and M. Rao, LncRNA GACAT3 promotes gastric cancer progression by negatively regulating miR-497 expression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 97 (2018) 136-142.
[34] B. Pan, M. Zhao, and L. Xu, Long noncoding RNA gastric cancer-associated transcript 3 plays oncogenic roles in glioma through sponging miR-3127-5p. Journal of cellular physiology 234 (2019) 8825-8833.
[35] H. Zhong, J. Yang, B. Zhang, X. Wang, L. Pei, L. Zhang, Z. Lin, Y. Wang, and C. Wang, LncRNA GACAT3 predicts poor prognosis and promotes cell proliferation in breast cancer through regulation of miR-497/CCND2. Cancer biomarkers : section A of Disease markers 22 (2018) 787-797.
[36] W. Zhou, L. Wang, Y. Miao, and R. Xing, Novel long noncoding RNA GACAT3 promotes colorectal cancer cell proliferation, invasion, and migration through miR-149. OncoTargets and therapy 11 (2018) 1543-1552.
[37] B. Zhou, W. Guo, C. Sun, B. Zhang, and F. Zheng, Linc00462 promotes pancreatic cancer invasiveness through the miR-665/TGFBR1-TGFBR2/SMAD2/3 pathway. Cell death & disease 9 (2018) 706.
[38] J. Gong, X. Qi, Y. Zhang, Y. Yu, X. Lin, H. Li, and Y. Hu, Long noncoding RNA linc00462 promotes hepatocellular carcinoma progression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 93 (2017) 40-47.